Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam.
Hogenhout R, de Vos II, Remmers S, Venderbos LDF, Busstra MB, Roobol MJ; ERSPC Rotterdam Study Group. Hogenhout R, et al. Among authors: de vos ii. Eur Urol Open Sci. 2022 Jul 2;42:42-49. doi: 10.1016/j.euros.2022.06.004. eCollection 2022 Aug. Eur Urol Open Sci. 2022. PMID: 35911085 Free PMC article.
Prostate cancer risk assessment by the primary care physician and urologist: transabdominal- versus transrectal ultrasound prostate volume-based use of the Rotterdam Prostate Cancer Risk Calculator.
de Vos II, Drost FH, Bokhorst LP, Alberts AR, van Gelder M, Herman EM, Boswinkel WD, Bangma CH, Roobol MJ. de Vos II, et al. Transl Androl Urol. 2023 Feb 28;12(2):241-248. doi: 10.21037/tau-22-640. Epub 2023 Feb 1. Transl Androl Urol. 2023. PMID: 36915892 Free PMC article.
A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.
de Vos II, Meertens A, Hogenhout R, Remmers S, Roobol MJ; ERSPC Rotterdam Study Group. de Vos II, et al. Eur Urol. 2023 Oct;84(4):426-434. doi: 10.1016/j.eururo.2023.03.016. Epub 2023 Apr 5. Eur Urol. 2023. PMID: 37029074 Free article. Clinical Trial.
From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life.
Hogenhout R, Remmers S, van Slooten-Midderigh ME, de Vos II, Roobol MJ; ERSPC Rotterdam Study Group. Hogenhout R, et al. Among authors: de vos ii. Eur Urol Oncol. 2023 Sep 8:S2588-9311(23)00172-4. doi: 10.1016/j.euo.2023.08.011. Online ahead of print. Eur Urol Oncol. 2023. PMID: 37690917 Free article.
Reply to Borivoj Golijanin, Anthony Mega, and Dragan Golijanin's Letter to the Editor re: Ivo I. de Vos, Sebastiaan Remmers, Renée Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam. Eur Urol 2024;85:74-81.
de Vos II, Remmers S, Roobol MJ. de Vos II, et al. Eur Urol. 2024 May;85(5):e142. doi: 10.1016/j.eururo.2024.01.020. Epub 2024 Feb 18. Eur Urol. 2024. PMID: 38369420 No abstract available.
Prevalence of Atopy following Mass Drug Administration with Albendazole: A Study in School Children on Flores Island, Indonesia.
Staal SL, Hogendoorn SKL, Voets SA, Tepper RC, Veenstra M, de Vos II, van Son KC, Gool JK, Paramitha AC, Aristyo K, Wildan A, Pratiwi C, van Ree R, Yazdanbakhsh M, Supali T, Djuardi Y, Labuda LA, Tahapary DL, Sartono E. Staal SL, et al. Among authors: de vos ii. Int Arch Allergy Immunol. 2018;177(3):192-198. doi: 10.1159/000490952. Epub 2018 Aug 21. Int Arch Allergy Immunol. 2018. PMID: 30130756 Free PMC article.